GLP-1 RA Use Tied to Better Kidney Transplant Outcomes in Patients With Diabetes

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on March 18, 2025.

By Lori Solomon HealthDay Reporter

TUESDAY, March 18, 2025 -- Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with better graft and patient survival among kidney transplant recipients with diabetes, according to a study published online March 5 in The Lancet Diabetes & Endocrinology.

Babak J. Orandi, M.D., Ph.D., from New York University in New York City, and colleagues examined the real-world safety and effectiveness of GLP-1 RA use in kidney transplant recipients with diabetes. The analysis included 18,016 kidney transplant recipients with diabetes (2013 through 2020) covered by Medicare, of whom 10.9 percent had at least one GLP-1 RA prescription filled posttransplant.

The researchers found that the five-year unadjusted cumulative incidence of death-censored graft loss from a cohort matched on survival time before GLP-1 RA initiation was 6.0 percent for GLP-1 RA users and 10.7 percent for nonusers. Based on a cohort matched on survival time before GLP-1 RA initiation, the five-year unadjusted cumulative incidence for mortality was 17.0 percent for GLP-1 RA users and 25.8 percent for nonusers. Use of GLP-1 RAs was associated with lower incidence of death-censored graft loss (adjusted subhazard ratio, 0.51) and lower mortality (adjusted hazard ratio, 0.69). GLP-1 RA use was not associated with safety end points, with the exception of diabetic retinopathy (adjusted hazard ratio, 1.49).

"Our study results are the strongest evidence to date that GLP-1 agonist drugs are largely safe and effective tools for addressing type 2 diabetes in kidney transplant recipients," Orandi said in a statement.

Several authors disclosed ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-03-19 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords